Meet our partners
Global Partner
Teva Pharmaceutical Industries
Teva is committed to increasing access to high-quality healthcare for people across the globe, at every stage of life. We do this by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. By integrating innovation, quality and accessibility, we improve health worldwide like no one else. Read more at

Mar 2016 Teva Announces Launch of Generic CampralĀ® in the United States

Mar 2016 Teva Receives European Commission Approval for the Allergan Generics Acquisition

Nov 2015 Teva and Takeda Establish Unique Partnership to Meet the Wide-Ranging Needs of Patients and Growing Importance of Generic Medicines Use in Japan

OneStart Europe Vision Film 2016

  • Aric Orbach, Head of Pharmacology, Teva Pharmaceutical Industries 
  • Dan Perez, CEO & Founder, Oxbridge Biotech Roundtable 
  • Nooman Haque, Director of Life Sciences, Silicon Valley Bank
  • Richard Mason, Head of Johnson & Johnson Innovation London, Johnson & Johnson 
  • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation - JJDC
  • Matthew Foy, Partner, SR One
  • Sarah Haywood, CEO, MedCity 
  • Matthias Essenpreis, CTO (Diagnostics), F-Hoffman-La Roche Ltd. 
  • Rachel Moss, Associate Principal, McKinsey and Company 
  • Claire Brown, Investment Manager, Alderley Park Ventures / BioCity 
  • Lynne Murray, Partnering and Strategy, MedImmune
  • Stephen Reese, Partner, Olswang LLP 
  • Ilan Zipkin, Investment Director, Takeda Ventures Inc. 

From the OneStart London Bootcamp 2016 

Panel Discussion

Panel Discussion: Accessing and Interacting with Industry

  • Rachel Moss, PhD, Associate Prinicipal, McKinsey and Company (Chair) 
  • Aric Orbach, DVM, Head of Pharmacology, Teva Pharmaceutical Industries 
  • Georg Buchner, PhD MBA, Licensing Director, Amgen 
  • Elena Fernandez-Kleinlein, Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation London 
  • Will West, PhD, President & CEO, Cancer Targeting Systems Inc. 
  • Claire Brown, PhD, Investment Manager, Alderley Park Ventures / BioCity 

From the OneStart San Francisco Bootcamp 2016 

Panel Discussion

Panel Discussion: Accessing and Interacting with Industry
  • Thomas Luby, PhD, Senior Director of New Ventures, Johnson & Johnson innovation, Boston (Chair)
  • David Wilson, PhD, VP Biologics, Teva Pharmaceuticals
  • Lucy Perez, PhD, Partner, McKinsey and Company
  • Sam Wu, Managing Director, MedImmune Ventures
  • Sharon Cload, VP Molecular Discovery Technologies, Bristol-Myers Squibb

David Wilson
VP Biologics Research at Teva Pharmaceuticals + more
Specialties: Biologics, therapeutic antibodies, target validation, cancer, protein engineering, combinatorial biology, structural biology, biochemistry, business development
Kobi Cohen
Director, Search & Evaluation, Global R&D at Teva Pharmaceutical Industries Ltd. + more
Business development oriented complemented by strong and wide scientific experience in Oncology, Neurology, Pain and Autoimmune/ inflammatory diseases. Highly experienced in preclinical development and scientific evaluation of preclinical and clinical data.
Aric Orbach
Head of Pharmacology at Teva Pharmaceuticals + more
I Graduated from the Koret School of Veterinary Medicine (Hebrew University) in 1995. Following my graduation I operated a veterinarian clinic and worked as a study director at Vetgenerics Research G. Ziv Ltd. I joined Teva in 2001 . Since then I have conducted various roles in the R&D, starting out in the non-clinical safety department then moving on to project leadership where I was responsible for development of projects at early stages. I am currently heading the pharmacological department. The unit is responsible for pharmacological investigation in pre-clinical models conducted as part of development process of novel drug candidates.
Teams Mentored